Idera Pharmaceuticals (IDRA) EPS Estimated At $-0.11, Shorts at Proteostasis Therapeutics (PTI) Raised By 20.1%

July 17, 2017 - By Kurt Siggers

Proteostasis Therapeutics Incorporated (NASDAQ:PTI) had an increase of 20.1% in short interest. PTI’s SI was 1.20M shares in July as released by FINRA. Its up 20.1% from 996,400 shares previously. With 152,100 avg volume, 8 days are for Proteostasis Therapeutics Incorporated (NASDAQ:PTI)’s short sellers to cover PTI’s short positions. The SI to Proteostasis Therapeutics Incorporated’s float is 9.53%. About 15,469 shares traded. Proteostasis Therapeutics Inc (NASDAQ:PTI) has declined 66.87% since July 17, 2016 and is downtrending. It has underperformed by 83.57% the S&P500.

Analysts expect Idera Pharmaceuticals Inc (NASDAQ:IDRA) to report $-0.11 EPS on August, 1.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.11 EPS. After having $-0.10 EPS previously, Idera Pharmaceuticals Inc’s analysts see 10.00% EPS growth. It is down 21.13% since July 17, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.

Among 2 analysts covering Idera Pharma (NASDAQ:IDRA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 3 analyst reports since January 6, 2016 according to SRatingsIntel. The rating was initiated by Wedbush with “Outperform” on Wednesday, January 6. The stock has “Outperform” rating by Wedbush on Wednesday, February 1.

Since May 1, 2017, it had 0 buys, and 1 sale for $1.02 million activity. Pillar Invest Corp sold $1.02 million worth of Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Monday, May 1.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company has market cap of $273.01 million. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor targeting technology and third-generation antisense (3GA) technology. It currently has negative earnings. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs.

Investors sentiment increased to 3.31 in 2016 Q4. Its up 1.26, from 2.05 in 2016Q3. It improved, as 9 investors sold Idera Pharmaceuticals Inc shares while 7 reduced holdings. 14 funds opened positions while 39 raised stakes. 96.26 million shares or 180.02% more from 34.38 million shares in 2016Q3 were reported. 29,718 are held by State Bank Of America De. Vanguard Inc holds 4.85M shares or 0% of its portfolio. Fmr Llc stated it has 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Nationwide Fund Advsr has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Sei Invs accumulated 0% or 450 shares. Palo Alto Investors invested in 616,355 shares. Blackrock invested in 0% or 7,295 shares. Millennium Mngmt Lc stated it has 463,024 shares. Private Advisor Gp Limited Com invested in 28,200 shares or 0% of the stock. Gru reported 51,198 shares. State Common Retirement Fund has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Architects Inc, New Jersey-based fund reported 4,525 shares. State Street has invested 0% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Meeder Asset accumulated 5,461 shares or 0% of the stock. Geode Cap Mgmt Ltd Limited Liability Company stated it has 867,504 shares or 0% of all its holdings.

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $120.45 million. The Firm is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It currently has negative earnings. It has developed the Disease Relevant Translation technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.